OBJECTIVES: To evaluate feasibility, safety, and outcome of patients treated with biodegradable biliary stents for benign biliary stenosis refractory to other treatments. METHODS: Between March 2011 and September 2012, ten patients (seven men, three women; age 59 ± 7 years) with recurrent cholangitis due to postsurgical biliary stricture, previous multiple unsuccessful (two to five) bilioplasties, and unsuitability for surgical/endoscopic repair underwent percutaneous implantation of a biodegradable biliary stent. Patients were followed-up clinically and with ultrasound at 1, 3 and 6 months, and then at 6-month intervals. RESULTS: Stent implantation was always feasible. No immediate major or minor complications occurred. In all patients, 48-h cholangiographic control demonstrated optimal stent positioning and stenosis resolution. In a median follow-up time of 16.5 months (25th-75th percentiles = 11-20.25 months) no further invasive treatment was needed. Three patients experienced transient episodes of cholangitis. Neither re-stenosis nor dilatation of the biliary tree was documented during follow-up. No stent was visible at the 6-month follow-up. CONCLUSIONS: Percutaneous placement of biodegradable biliary stents represents a new option in treating benign biliary stenoses refractory to treatment with bilioplasty. This technique seems to be feasible, effective and free from major complications. Further investigations are warranted to confirm our preliminary results.
OBJECTIVES: To evaluate feasibility, safety, and outcome of patients treated with biodegradable biliary stents for benign biliary stenosis refractory to other treatments. METHODS: Between March 2011 and September 2012, ten patients (seven men, three women; age 59 ± 7 years) with recurrent cholangitis due to postsurgical biliary stricture, previous multiple unsuccessful (two to five) bilioplasties, and unsuitability for surgical/endoscopic repair underwent percutaneous implantation of a biodegradable biliary stent. Patients were followed-up clinically and with ultrasound at 1, 3 and 6 months, and then at 6-month intervals. RESULTS: Stent implantation was always feasible. No immediate major or minor complications occurred. In all patients, 48-h cholangiographic control demonstrated optimal stent positioning and stenosis resolution. In a median follow-up time of 16.5 months (25th-75th percentiles = 11-20.25 months) no further invasive treatment was needed. Three patients experienced transient episodes of cholangitis. Neither re-stenosis nor dilatation of the biliary tree was documented during follow-up. No stent was visible at the 6-month follow-up. CONCLUSIONS: Percutaneous placement of biodegradable biliary stents represents a new option in treating benign biliary stenoses refractory to treatment with bilioplasty. This technique seems to be feasible, effective and free from major complications. Further investigations are warranted to confirm our preliminary results.
Authors: Johanna M Laukkarinen; Juhani A Sand; Pierce Chow; Hanne Juuti; Minna Kellomäki; Päivi Kärkkäinen; Jorma Isola; Sidney Yu; Satchithanantham Somanesan; Irene Kee; In Chin Song; Teck Hin Ng; Isto H Nordback Journal: J Gastrointest Surg Date: 2007-06 Impact factor: 3.452
Authors: G Mauri; L M Sconfienza; B Fiore; G Brambilla; V Pedicini; D Poretti; R F Lutman; M Montorsi; F Sardanelli Journal: Clin Radiol Date: 2012-05-19 Impact factor: 2.350
Authors: Giovanni Mauri; Lorenzo C Pescatori; Chiara Mattiuz; Dario Poretti; Vittorio Pedicini; Fabio Melchiorre; Umberto Rossi; Luigi Solbiati; Luca Maria Sconfienza Journal: Radiol Med Date: 2016-10-17 Impact factor: 3.469
Authors: Miguel A De Gregorio; Eva Criado; Jose A Guirola; Enrique Alvarez-Arranz; Mercedes Pérez-Lafuente; Marta Barrufet; Maria D Ferrer-Puchol; Sandra Lopez-Minguez; Jose Urbano; Carlos Lanciego; Alexander Aguinaga; Antonio Capel; Maria D Ponce-Dorrego; Abel Gregorio Journal: Eur Radiol Date: 2020-03-27 Impact factor: 5.315
Authors: Marco Das; Christiaan van der Leij; Marcus Katoh; Daniel Benten; Babs M F Hendriks; Adam Hatzidakis Journal: Cardiovasc Intervent Radiol Date: 2021-07-29 Impact factor: 2.740